Supplemental Figure 1 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in &Lt;i>etv6-Ntrk3–positive Acute Myeloid Leukemia

Kristen M. Smith,Patrick C. Fagan,Elena Pomari,Giuseppe Germanò,Chiara Frasson,Colin Walsh,Ian M. Silverman,Paolo Bonvini,Gang Li

DOI: https://doi.org/10.1158/1535-7163.22504585.v1

2023-01-01

Abstract:Characterization of ETV6-NTRK3-driven AML cell lines.

What problem does this paper attempt to address?

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Jiannong Li,Inna Smalley,Zhihua Chen,Jheng-Yu Wu,Manali S. Phadke,Jamie K. Teer,Thanh Nguyen,Florian A. Karreth,John M. Koomen,Amod A. Sarnaik,Jonathan S. Zager,Nikhil I. Khushalani,Ahmad A. Tarhini,Vernon K. Sondak,Paulo C. Rodriguez,Jane L. Messina,Y. Ann Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22486712

2023-01-01

Abstract:Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Andrea Sartore-Bianchi,Elena Ardini,Roberta Bosotti,Alessio Amatu,Emanuele Valtorta,Alessio Somaschini,Laura Raddrizzani,Laura Palmeri,Patrizia Banfi,Erica Bonazzina,Sandra Misale,Giovanna Marrapese,Antonella Leone,Rachele Alzani,David Luo,Zachary Hornby,Jonathan Lim,Silvio Veronese,Angelo Vanzulli,Alberto Bardelli,Marcella Martignoni,Cristina Davite,Arturo Galvani,Antonella Isacchi,Salvatore Siena

DOI: https://doi.org/10.1093/jnci/djv306

2015-11-12

Abstract:In metastatic colorectal cancer (CRC), actionable genetic lesions represent potential clinical opportunities. NTRK1, 2, and 3 gene rearrangements encode oncogenic fusions of the tropomyosin-receptor kinase (TRK) family of receptor tyrosine kinases in different tumor types. The TPM3-NTRK1 rearrangement is a recurring event in CRC that renders tumors sensitive to TRKA kinase inhibitors in preclinical models. We identified abnormal expression of the TRKA protein in tumor and liver metastases of a CRC patient refractory to standard therapy. Molecular characterization unveiled a novel LMNA-NTRK1 rearrangement within chromosome 1 with oncogenic potential, and the patient was treated with the pan-TRK inhibitor entrectinib, achieving partial response with decrease in hepatic target lesions from 6.8 and 8.2cm in longest diameter to 4.7 and 4.3cm, respectively. To our knowledge, this is the first clinical evidence of efficacy for therapeutic inhibition of TRKA in a solid tumor, illuminating a genomic-driven strategy to identify CRCs reliant on this oncogene to be clinically targeted with entrectinib.

oncology
Supplementary Figure 2 from RON Receptor Tyrosine Kinase As a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE

Sreedhar Reddy Suthe,Hang-Ping Yao,Tian-Hao Weng,Chen-Yu Hu,Liang Feng,Zhi-Gang Wu,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22505502.v1

2023-01-01

Abstract:Fig. S2 is about the cytotoxic effect of Zt/g4-MMAE on a panel of TNBC cell lines
Supplementary Figure 4 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389591.v1

2023-01-01

Abstract:PDF file - 175K, Activation and ALK inhibitor sensitivity of down stream molecules in 293T cells expressing ALK and FN1-ALK
Supplementary Figure 5 from Identification of Anaplastic Lymphoma Kinase As a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389588

2023-01-01

Abstract:PDF file - 45K, ALK and FN1-ALK tumors are sensitive to TAE684 treatment
Supplementary Figure 1 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy Against Acute Lymphoblastic Leukemia in Vitro and in Vivo

Sandra Christoph,Deborah DeRyckere,Jennifer Schlegel,J. Kimble Frazer,Lance A. Batchelor,Alesia Y. Trakhimets,Susan Sather,Debra Hunter,Christopher T. Cummings,Jing Liu,Yang Liu,Dmitri Kireev,Catherine Simpson,Jacqueline Norris-Drouin,Emily A. Hull-Ryde,William P. Janzen,Gary L. Johnson,Xiaodong Wang,Stephen V. Frye,H. Shelton Earp,Douglas K. Graham

DOI: https://doi.org/10.1158/1535-7163.22498875.v1

2023-01-01

Abstract:PDF - 294KB, TAM receptor expression in Jurkat cell line was detected by western blot analysis. Whole cell lysates were prepared and phosphorylated (denoted by p-) and total proteins were detected. Western blots representative of three independent experiments are shown. Blots were stripped and reprobed with anti-tubulin antibody to confirm similar protein loading.
ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature

Wusheng Zhang,Sen Tian,Xiang Li,Yilin Chen,Xinyu Wang,Yunshuo Zhang,Lihui Lv,Yonghua Li,Hui Shi,Chong Bai

DOI: https://doi.org/10.1016/j.cllc.2024.03.005

IF: 4.84

2024-04-08

Clinical Lung Cancer

Abstract:Pulmonary atypical carcinoid (AC) is an extremely rare neuroendocrine tumor. The neurotrophic tropomyosin receptor kinase (NTRK) fusions are reported in only 0.5% of nonsmall cell lung cancer, and are more rare in AC with only one previously reported case. Currently, there is little established evidence on the optimal therapeutic strategies and prognosis for advanced cases. We present a female patient with metastatic AC after complete resection. Due to low expression of somatostatin receptor in this case, somatostatin analogs and peptide receptor radionuclide therapy were not available. After pursuing other alternative treatments, including chemotherapy (ie, carboplatin, etoposide, capecitabine, temozolomide, and paclitaxel), everolimus, and atezolizumab, she returned with significant progression, including innumerable subcutaneous nodules, left pleura metastasis, multiple bone metastases, and brain metastases. New biopsy analysis revealed an ETV6-NTRK2 fusion. She was immediately administered the first-generation tropomyosin receptor kinase inhibitor entrectinib at a dose of 600 mg q.d. A subsequent month of treatment resulted in a complete response in all of the metastatic lung lesions. To date, she has maintained sustained benefit for at least 1 year from initiation of entrectinib. Here, we present the first case of a female patient with metastatic AC harboring the ETV6-NTRK2 fusion, and successfully treated with entrectinib, providing evidence for the application of entrectinib in patients with NTRK-positive AC, and underscoring the critical role of molecular profiling for such cases.

oncology
Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations

Hui-Dan Li,Si-Si Chen,Jing Ding,Chun-Ling Zhang,Hui-Yin Qiu,Xin-Xin Xia,Jun Yang,Xiao-Rui Wang

DOI: https://doi.org/10.1007/s00277-024-05917-3

Abstract:ETV6::ABL1 is a rare fusion gene that found in MPN, ALL, and AML. It has a complex and diverse formation mechanism due to the reciprocal orientations of the ETV6 and ABL1 genes relative to the centromeres. NPM1 is frequently mutated in adult AML, often accompanied by FLT3-ITD, which suggests molecular synergisms in AML pathogenesis. Previous reports on ETV6::ABL1 mostly focus on FLT3-ITD. In this study, we present a case of AML with ETV6::ABL1, along with NPM1 and FLT3-ITD. The patient showed a rapid increase in primitive cells at the initial stage, along with the presence of immature granulocytes and erythrocytes. Through cytogenetic analysis, fluorescence in situ hybridization (FISH), and RNA-seq, we elucidated the mechanism behind the formation of the ETV6::ABL1 fusion gene. Despite conventional chemotherapy failure and rapid tumor proliferation, we attempted to add FLT3 inhibitor sorafenib to the treatment, along with chemotherapy bridging to haploidentical transplantation. After haplo-HSCT, a combination of sorafenib and dasatinib was administered as maintenance therapy. The patient achieved complete remission (CR) and maintained it for 11 months. The intricate genetic landscape observed in this case presents diagnostic dilemmas and therapeutic challenges, emphasizing the importance of a comprehensive understanding of its implications for disease classification, risk stratification, and treatment selection.
Supplementary Figure 3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389594.v1

2023-01-01

Abstract:PDF file - 129K, A novel fusion: FN1-ALK
Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu,Eiki Kikuchi,Chunxiao Xu,Hiromichi Ebi,Dalia Ercan,Katherine A. Cheng,Robert Padera,Jeffrey A. Engelman,Pasi A. Jänne,Geoffrey I. Shapiro,Takeshi Shimamura,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22391819.v1

2023-01-01

Abstract:PDF file - 1.4MB, Supplemental Figure 1. MET is inducible in MET, TD/MET, and TL/MET models Supplemental Figure 2. Quantification of hMET expression in mouse models Supplemental Figure 3. Comparison of the tumor counts in mutant EGFR lung tumors with or without expression of hMET. Supplemental Figure 4. Representative MRI images prior to and after treatment in TL and TL/MET mice. Supplemental Figure 5. Xenografts of HCC827GR6 cells ectopically expressing EGFR E746_A750del/T790M are sensitive to the combination of WZ4002 and 17-DMAG. Supplemental Figure 6. The WZ4002/crizotinib or WZ4002/17-DMAG combinations suppress phosphorylation of EGFR, Akt, and Erk in TD and TD/MET to a greater extent than individual treatments
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

A Drilon,G Li,S Dogan,M Gounder,R Shen,M Arcila,L Wang,D M Hyman,J Hechtman,G Wei,N R Cam,J Christiansen,D Luo,E C Maneval,T Bauer,M Patel,S V Liu,S H I Ou,A Farago,A Shaw,R F Shoemaker,J Lim,Z Hornby,P Multani,M Ladanyi,M Berger,N Katabi,R Ghossein,A L Ho

DOI: https://doi.org/10.1093/annonc/mdw042

Abstract:Background: Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity. We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as MASC after next-generation sequencing revealed an ETV6-NTRK3 fusion. Patients and methods: This alteration was targeted with the pan-Trk inhibitor entrectinib (Ignyta), which possesses potent in vitro activity against cell lines containing various NTRK1/2/3 fusions. Results: A dramatic and durable response was achieved with entrectinib in this patient, followed by acquired resistance that correlated with the appearance of a novel NTRK3 G623R mutation. Structural modeling predicts that this alteration sterically interferes with drug binding, correlating to decreased sensitivity to drug inhibition observed in cell-based assays. Conclusions: This first report of clinical activity with TrkC inhibition and the development of acquired resistance in an NTRK3-rearranged cancer emphasize the utility of comprehensive molecular profiling and targeted therapy for rare malignancies (NCT02097810).
Supplementary Figure 1 from Lung Cancers with Concomitant egfr Mutations and alk Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Jin-Ji Yang,Xu-Chao Zhang,Jian Su,Chong-Rui Xu,Qing Zhou,Hong-Xia Tian,Zhi Xie,Hua-Jun Chen,Yi-Sheng Huang,Ben-Yuan Jiang,Zhen Wang,Bin-Chao Wang,Xue-Ning Yang,Wen-Zhao Zhong,Qiang Nie,Ri-Qiang Liao,Tony S. Mok,Yi-Long Wu

DOI: https://doi.org/10.1158/1078-0432.22448817.v1

2023-01-01

Abstract:PDF file - 635KB, Sequence results of EML4-ALK fusion variants.
Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter,Robert Tjin Tham Sjin,Henry J. Haringsma,Kadoaki Ohashi,Jing Sun,Kwangho Lee,Aleksandr Dubrovskiy,Matthew Labenski,Zhendong Zhu,Zhigang Wang,Michael Sheets,Thia St Martin,Russell Karp,Dan van Kalken,Prasoon Chaturvedi,Deqiang Niu,Mariana Nacht,Russell C. Petter,William Westlin,Kevin Lin,Sarah Jaw-Tsai,Mitch Raponi,Terry Van Dyke,Jeff Etter,Zoe Weaver,William Pao,Juswinder Singh,Andrew D. Simmons,Thomas C. Harding,Andrew Allen

DOI: https://doi.org/10.1158/2159-8290.22530291.v1

2023-01-01

Abstract:Supplementary Figure 7 - PDF file 352K, H&E and immunohistochemical (Ki67) staining of tumors derived from EGFR mutant GEM models
Supplementary Figure 3 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Tsuyoshi Yoshida,Guolin Zhang,Matthew A. Smith,Alex S. López,Yun Bai,Jiannong Li,Bin Fang,John M. Koomen,Bhupendra Rawal,Kate Fisher,Ann Y. Chen,Michiko Kitano,Yume Morita,Haruka Yamaguchi,K. Shibata,Takafumi Okabe,Isamu Okamoto,Kazuhiko Nakagawa,Eric B. Haura

DOI: https://doi.org/10.1158/1078-0432.22451534

2023-01-01

Abstract:PDF file - 387KB, Effects of ligands exposure with or without EGFR-TKI in PC9 and PC9GR cells. A-F: PC9 (A, C, and E) or PC9GR cells (B, D, and F) were incubated for 1 hour in the absence or presence of 100 nM erlotinib (A, C, and E) or afatinib (B, D, and F) with indicated concentrations of HGF (A and B), IGF1 (C and D), or Gas6 (E and F). Cell lysates were subjected to protein expression analysis with antibodies to pMET (A and B), IGF1R (C and D), or pAXL (E and F) along with pEGFR, pAkt, pErk, and antibodies to β-actin as a loading control.
Supplementary Figure 4 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Takeshi Yoshida,Guolin Zhang,Matthew A. Smith,Alex S. Lopez,Yun Bai,Jiannong Li,Bin Fang,John Koomen,Bhupendra Rawal,Kate J. Fisher,Ann Y. Chen,Michiko Kitano,Yume Morita,Haruka Yamaguchi,Kiyoko Shibata,Takafumi Okabe,Isamu Okamoto,Kazuhiko Nakagawa,Eric B. Haura

DOI: https://doi.org/10.1158/1078-0432.22451531

2023-01-01

Abstract:PDF file - 139KB, Effects of ligands exposure with or without EGFR-TKI in PC9 and PC9GR cells. A-F: PC9 (A, C, and E) or PC9GR cells (B, D, and F) were incubated for 1 hour in the absence or presence of 100 nM erlotinib (A, C, and E) or afatinib (B, D, and F) with indicated concentrations of HGF (A and B), IGF1 (C and D), or Gas6 (E and F). Cell lysates were subjected to protein expression analysis with antibodies to pMET (A and B), IGF1R (C and D), or pAXL (E and F) along with pEGFR, pAkt, pErk, and antibodies to β-actin as a loading control.
Supplementary Figure legend from ETV1-Positive Cells Give Rise to BRAFV600E-Mutant Gastrointestinal Stromal Tumors

Leili Ran,Devan Murphy,Jessica Sher,Zhen Cao,Shangqian Wang,Edward Walczak,Youxin Guan,Yuanyuan Xie,Shipra Shukla,Yu Zhan,Cristina R. Antonescu,Yu Chen,Ping Chi

DOI: https://doi.org/10.1158/0008-5472.22414656.v1

2023-01-01

Abstract:Supplementary Figure legend
Supplemental Figures S1-S2 from Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis

Julia E. Maxson,Melissa L. Abel,Jinhua Wang,Xianming Deng,Sina Reckel,Samuel B. Luty,Huahang Sun,Julie Gorenstein,Seamus B. Hughes,Daniel Bottomly,Beth Wilmot,Shannon K. McWeeney,Jerald Radich,Oliver Hantschel,Richard E. Middleton,Nathanael S. Gray,Brian J. Druker,Jeffrey W. Tyner

DOI: https://doi.org/10.1158/0008-5472.22406454

2023-01-01

Abstract:Hitwalker diagram from CMML patient sample 10-210 (S1); EGFR binding domain of Tnk2 (S2).
Supplementary Figure 1 from NLRR1 Enhances EGF-Mediated MYCN Induction in Neuroblastoma and Accelerates Tumor Growth In Vivo

Shamim Hossain,Atsushi Takatori,Yohko Nakamura,Yusuke Suenaga,Takehiko Kamijo,Akira Nakagawara

DOI: https://doi.org/10.1158/0008-5472.22394906

2023-01-01

Abstract:PDF file, 103K, EGF-mediated phosphorylation of EGFR and ERK. EGF stimulation enhances EGFR phosphorylation in the cells. U0126 and AG1478 effectively inhibit EGF-mediated phosphorylation of ERK and EGFR, respectively.

Supplemental Figure 1 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in &Lt;i>etv6-Ntrk3</i>–positive Acute Myeloid Leukemia

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

Supplementary Figure 2 from RON Receptor Tyrosine Kinase As a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE

Supplementary Figure 4 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figure 5 from Identification of Anaplastic Lymphoma Kinase As a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figure 1 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy Against Acute Lymphoblastic Leukemia <i>in Vitro</i> and <i>in Vivo</i>

ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature

Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations

Supplementary Figure 3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Supplementary Figure 1 from Lung Cancers with Concomitant <i>egfr</i> Mutations and <i>alk</i> Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 3 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Supplementary Figure 4 from Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Supplementary Figure legend from ETV1-Positive Cells Give Rise to <i>BRAF<sup>V600E</sup></i>-Mutant Gastrointestinal Stromal Tumors

Supplemental Figures S1-S2 from Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis

Supplementary Figure 1 from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Supplemental Figure 1 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in &Lt;i&gt;etv6-Ntrk3&lt;/i&gt;–positive Acute Myeloid Leukemia